If you are looking for the best ideas for your portfolio you may want to consider some of Del Principe O’Brien Financial Advisors top stock picks. Del Principe O’Brien Financial Advisors, an investment management firm, is bullish on Danaher Corp (NYSE:DHR) stock. In its Q2 2019 investor letter – you can download a copy here – the firm discussed its investment thesis on Danaher Corp (NYSE:DHR) stock. Danaher Corp (NYSE:DHR) designs, manufactures and markets professional, medical, industrial and commercial products and services.
In August 2019, Del Principe O’Brien Financial Advisors had released its Q2 2019 investor letter. Danaher Corp (NYSE:DHR) stock has posted a return of 42.7% in the trailing one year period, outperforming the S&P 500 Index which returned 9.0% in the same period. This suggests that the investment firm was right in its decision. On a year-to-date basis, Danaher Corp (NYSE:DHR) stock has risen by 32.7%.
In Q2 2019 investor letter, Del Principe O’Brien Financial Advisors said the fund posted a return of 7.1% in the second quarter of 2019, outperforming the S&P 500 Index which returned 4.30% in the same period. Let’s take a look at comments made by Del Principe O’Brien Financial Advisors about Danaher Corp (NYSE:DHR) stock in the Q2 2019 investor letter.
“Danaher designs, manufactures, and markets life sciences, diagnostics, dental, environmental, and applied solutions worldwide. Danaher has proven to be an adept acquirer, completing more than 200 deals over the last ten years with very little disruption. The Rales brothers, who founded Danaher, are experts in capital allocation. They build their wealth through leveraged buyouts and tax-efficient restructurings. If you invested $10,000 in Danaher in 1990, it would be worth more than $800,000 today. That is a 27-year compound annual growth rate (CAGR) of 18%.
In February 2019 on rumors of a large acquisition, Danaher stock went from $98 to $135. Indeed, the company did make a large acquisition that month, purchasing the biopharma business of General Electric’s Life Sciences division for $21.4 billion. GE Biopharma provides instruments, consumables, and software that support the research, development, and manufacturing of biopharmaceutical drugs. The purchase further expands Danaher’s life science offerings. Since that deal, we have realized a gain of 78%.”
In Q2 2020, the number of bullish hedge fund positions on Danaher Corp (NYSE:DHR) stock increased by about 21% from the previous quarter (see the chart here), so a number of other hedge fund managers seem to agree with Danaher’s growth potential. Our calculations showed that Danaher Corp (NYSE:DHR) isn’t ranked among the 30 most popular stocks among hedge funds.
The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.
Video: Top 5 Stocks Among Hedge Funds
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. You can subscribe to our free enewsletter below to receive our stories in your inbox:
Disclosure: None. This article is originally published at Insider Monkey.